Coya Therapeutics Inc

For the period ended Mar 31, 2024. Filed May 9, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 9, 2024

COYA$2.99+6.4%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Contents

Item 1. Financial Statements

CONDENSED BALANCE SHEETS

	March 31,	December 31,
	2024	2023
(unaudited)
Assets
Current assets:
Cash and cash equivalents	$35,989,406	$32,626,768
Collaboration receivable	-	7,500,000
Prepaids and other current assets	1,344,955	1,069,557
Total current assets	37,334,361	41,196,325
Fixed assets, net	59,109	65,949
Total assets	$37,393,470	$41,262,274
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$1,587,943	$1,155,656
Accrued expenses	2,041,530	2,973,215
Deferred collaboration revenue	689,669	923,109
Total current liabilities	4,319,142	5,051,980
Deferred collaboration revenue	681,287	574,685
Total liabilities	5,000,429	5,626,665
Commitments and contingencies (Note 6)
Stockholders' equity:
Series A convertible preferred stock, $0.0001 par value: 10,000,000 shares authorized, none issued or outstanding as of March 31, 2024 or December 31, 2023	-	-
Common stock, $0.0001 par value; 200,000,000 shares authorized; 14,613,172 and 14,405,325 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	1,462	1,441
Additional paid-in capital	63,449,125	61,501,801
Subscription receivable	(149,250)	(11,250)
Accumulated deficit	(30,908,296)	(25,856,383)
Total stockholders' equity	32,393,041	35,635,609
Total liabilities and stockholders' equity	$37,393,470	$41,262,274

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.